Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HealtheTech cost-cutting

This article was originally published in The Gray Sheet

Executive Summary

Reduction of 25% in operating expenses will be achieved by third quarter of 2003, as the Golden, Colo.-based device firm targets a headcount reduction for "most areas of the company," a May 6 release notes. Citing disappointing sales of BalanceLog software via its retail channel, HealtheTech announces revised guidance and restructuring plans to focus on medical and commercial weight management, withdrawing from mass retail software distribution altogether. The company also will cut R&D expenditures related to products such asFitGem, and will introduce lower-cost versions of its BodyGem and MedGem devices. HealtheTech went public in July 2002 (1"The Gray Sheet" July 15, 2002, p. 9)...

You may also be interested in...



Financings In Brief

Boston Scientific: Increase of equity position in paclitaxel supplier Natural Pharmaceuticals, Inc. through the acquisition of additional shares builds on exclusive August 2001 supply agreement, Boston Scientific says (1"The Gray Sheet" August 20, 2001, p. 9). Privately held NPI, which has a proprietary technology for extracting paclitaxel from yew trees, has granted Boston Scientific a "long-term" extension. "We are very pleased to be extending our relationship with NPI, particularly in light of the growing body of evidence that paclitaxel appears to be a safe and effective treatment for coronary artery disease," Boston Scientific Chief Technology Officer Fred Colen comments July 9. Specific terms of the deal are not being disclosed...

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel